Early initiation of basal insulin did not impact cardiovascular outcomes compared to standard management of glucose in patients with type 2 diabetes or elevated fasting glucose with cardiovascular risk factors.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Early therapy with basal insulin does not reduce cardiovascular outcomes in dysglycemic patients

Newsletter